ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01708603
Recruitment Status : Terminated (Sponsor decision)
First Posted : October 17, 2012
Last Update Posted : August 14, 2015
Sponsor:
Information provided by (Responsible Party):
Amgen

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : September 2014
  Estimated Study Completion Date : August 2015
  Certification/Extension First Submitted : April 20, 2015

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 October 31, 2016 December 23, 2016
2 April 6, 2017 May 15, 2017
3 December 8, 2017 January 8, 2018